A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer

A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis

(2015) Pei-Fang Wu et al.   BMC CANCER

Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy

(2015) Y.-S. Lu et al.   CLINICAL CANCER RESEARCH

Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience

(2015) Otto M. Henriksen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Dynamic18F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts

(2013) Alexandr Kristian et al.   ACTA ONCOLOGICA

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

(2013) B. Gerber et al.   ANNALS OF ONCOLOGY

Markers of Response for the Antiangiogenic Agent Bevacizumab

(2013) Diether Lambrechts et al.   JOURNAL OF CLINICAL ONCOLOGY

Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications

(2013) Rajan Jain   NMR IN BIOMEDICINE

Recurrent Glioblastoma: Optimum Area under the Curve Method Derived from Dynamic Contrast-enhanced T1-weighted Perfusion MR Imaging

(2013) Won Jung Chung et al.   RADIOLOGY

Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target

(2012) B. Sitohy et al.   CANCER RESEARCH

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

(2012) James P. B. O'Connor et al.   Nature Reviews Clinical Oncology

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan

(2012) C. Colavolpe et al.   NEURO-ONCOLOGY

Targeting Angiogenesis in Metastatic Breast Cancer

(2012) S. Reddy et al.   ONCOLOGIST

Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients

(2011) Bang-Bin Chen et al.   EUROPEAN RADIOLOGY

Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion

(2011) J. Narang et al.   NEURO-ONCOLOGY

Dynamic Contrast-enhanced MR Imaging Measurement of Vertebral Bone Marrow Perfusion May Be Indicator of Outcome of Acute Myeloid Leukemia Patients in Remission

(2011) Bang-Bin Chen et al.   RADIOLOGY

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

(2010) A. Chan et al.   ANNALS OF ONCOLOGY

Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer

(2010) D. G. Duda et al.   ONCOLOGIST

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

(2009) Christopher G. Willett et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

(2008) J. Ma et al.   MOLECULAR CANCER THERAPEUTICS

Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria

(2008) Junichi Kamiie et al.   PHARMACEUTICAL RESEARCH